Progress and challenges for treating Type 1 diabetes. (July 2016)

• Record Type: Journal Article
• Authors: Garyu, Justin W.; Meffre, Eric; Cotsapas, Chris; Herold, Kevan C.
• Is Part Of: Journal of autoimmunity. Volume 71(2016)
• Page Start: 1
• Page End: 9
• Publication Date: 2016-07
• Subjects: Type 1 diabetes -- Autoimmunity -- Tolerance -- Immune therapy; Autoimmunity -- Periodicals; Autoimmune diseases -- Periodicals; Autoantibodies -- Periodicals; Autoimmune Diseases -- Periodicals; Auto-immunité -- Périodiques; Maladies auto-immunes -- Périodiques; Electronic journals; 616.978005
• DOI: 10.1016/j.jaut.2016.04.004
• Languages: English
• ISSNs: 0896-8411

Abstract

Abstract: It has been more than 30 years since the initial trials of Cyclosporin A to treat patients with new onset Type 1 diabetes (T1D). Since that time, there have been insights into genetic predisposition to the disease, the failures of immune tolerance, and mechanisms that cause the immune mediated β cell destruction. The genetic loci associated affect lymphocyte development and tolerance mechanisms. Discoveries related to the roles of specific immune responses gene such as the major histocompatibility complex, PTPN22, CTLA-4, IL-2RA, as well as the mechanisms of antigen presentation in the thymus have suggested ways in which autoreactivity may follow changes in the functions of these genes that are associated with risk. Antigens that are recognized by the immune system in patients with T1D have been identified. With this information, insights into the novel cellular mechanisms leading to the initiation and orchestration of β cell killing have been developed such as the presentation of unique antigens within the islets. Clinical trials have been performed, some of which have shown efficacy in improving β cell function but none have been able to permanently prevent loss of insulin secretion. The reasons for the lack of long term success are not clear but may include the heterogeneity of the immune response and in individual responses to immune therapies, recurrence of autoimmunity after the initial effects of the therapies, or even intrinsic mechanisms of β cell death that proceeds independently of immune attack after initiation of the disease. In this review, we cover developments that have led to new therapeutics and characteristics of patients who may show the most benefits from therapies. We also identify areas of incomplete understanding that might be addressed to develop more effective therapeutic strategies. Highlights: There has been progress in understanding the genetics, molecular, and cellular mechanisms of Type 1 diabetes. Some clinical trials have modified the natural progression of the disease. However none have resulted in permanent remission. Drug combinations, selection of likely responders, and careful timing of therapy may improve long term outcomes of trials.